Cargando…

Emerging pharmaceutical therapies for COPD

COPD, for which cigarette smoking is the major risk factor, remains a worldwide burden. Current therapies provide only limited short-term benefit and fail to halt progression. A variety of potential therapeutic targets are currently being investigated, including COPD-related proinflammatory mediator...

Descripción completa

Detalles Bibliográficos
Autores principales: Lakshmi, Sowmya P, Reddy, Aravind T, Reddy, Raju C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531723/
https://www.ncbi.nlm.nih.gov/pubmed/28790817
http://dx.doi.org/10.2147/COPD.S121416
_version_ 1783253397955149824
author Lakshmi, Sowmya P
Reddy, Aravind T
Reddy, Raju C
author_facet Lakshmi, Sowmya P
Reddy, Aravind T
Reddy, Raju C
author_sort Lakshmi, Sowmya P
collection PubMed
description COPD, for which cigarette smoking is the major risk factor, remains a worldwide burden. Current therapies provide only limited short-term benefit and fail to halt progression. A variety of potential therapeutic targets are currently being investigated, including COPD-related proinflammatory mediators and signaling pathways. Other investigational compounds target specific aspects or complications of COPD such as mucus hypersecretion and pulmonary hypertension. Although many candidate therapies have shown no significant effects, other emerging therapies have improved lung function, pulmonary hypertension, glucocorticoid sensitivity, and/or the frequency of exacerbations. Among these are compounds that inhibit the CXCR2 receptor, mitogen-activated protein kinase/Src kinase, myristoylated alanine-rich C kinase substrate, selectins, and the endothelin receptor. Activation of certain transcription factors may also be relevant, as a large retrospective cohort study of COPD patients with diabetes found that the peroxisome proliferator-activated receptor γ (PPARγ) agonists rosiglitazone and pioglitazone were associated with reduced COPD exacerbation rate. Notably, several therapies have shown efficacy only in identifiable subgroups of COPD patients, suggesting that subgroup identification may become more important in future treatment strategies. This review summarizes the status of emerging therapeutic pharmaceuticals for COPD and highlights those that appear most promising.
format Online
Article
Text
id pubmed-5531723
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-55317232017-08-08 Emerging pharmaceutical therapies for COPD Lakshmi, Sowmya P Reddy, Aravind T Reddy, Raju C Int J Chron Obstruct Pulmon Dis Review COPD, for which cigarette smoking is the major risk factor, remains a worldwide burden. Current therapies provide only limited short-term benefit and fail to halt progression. A variety of potential therapeutic targets are currently being investigated, including COPD-related proinflammatory mediators and signaling pathways. Other investigational compounds target specific aspects or complications of COPD such as mucus hypersecretion and pulmonary hypertension. Although many candidate therapies have shown no significant effects, other emerging therapies have improved lung function, pulmonary hypertension, glucocorticoid sensitivity, and/or the frequency of exacerbations. Among these are compounds that inhibit the CXCR2 receptor, mitogen-activated protein kinase/Src kinase, myristoylated alanine-rich C kinase substrate, selectins, and the endothelin receptor. Activation of certain transcription factors may also be relevant, as a large retrospective cohort study of COPD patients with diabetes found that the peroxisome proliferator-activated receptor γ (PPARγ) agonists rosiglitazone and pioglitazone were associated with reduced COPD exacerbation rate. Notably, several therapies have shown efficacy only in identifiable subgroups of COPD patients, suggesting that subgroup identification may become more important in future treatment strategies. This review summarizes the status of emerging therapeutic pharmaceuticals for COPD and highlights those that appear most promising. Dove Medical Press 2017-07-21 /pmc/articles/PMC5531723/ /pubmed/28790817 http://dx.doi.org/10.2147/COPD.S121416 Text en © 2017 Lakshmi et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Lakshmi, Sowmya P
Reddy, Aravind T
Reddy, Raju C
Emerging pharmaceutical therapies for COPD
title Emerging pharmaceutical therapies for COPD
title_full Emerging pharmaceutical therapies for COPD
title_fullStr Emerging pharmaceutical therapies for COPD
title_full_unstemmed Emerging pharmaceutical therapies for COPD
title_short Emerging pharmaceutical therapies for COPD
title_sort emerging pharmaceutical therapies for copd
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531723/
https://www.ncbi.nlm.nih.gov/pubmed/28790817
http://dx.doi.org/10.2147/COPD.S121416
work_keys_str_mv AT lakshmisowmyap emergingpharmaceuticaltherapiesforcopd
AT reddyaravindt emergingpharmaceuticaltherapiesforcopd
AT reddyrajuc emergingpharmaceuticaltherapiesforcopd